Yitong Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4454756/publications.pdf

Version: 2024-02-01

27	1,162	471061 17	552369 26
papers	citations	h-index	g-index

27	27	27	2010
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In silico evaluation of pharmacokinetics and acute toxicity of withanolides in Ashawagandha. Phytochemistry Letters, 2022, 47, 130-135.	0.6	3
2	Use In Silico and In Vitro Methods to Screen Hepatotoxic Chemicals and CYP450 Enzyme Inhibitors. Methods in Molecular Biology, 2022, 2474, 189-198.	0.4	1
3	Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells. Methods in Molecular Biology, 2022, 2474, 39-46.	0.4	0
4	Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitro. Journal of Applied Toxicology, 2021, 41, 1438-1445.	1.4	11
5	Liver toxicity of anthraquinones: A combined in vitro cytotoxicity and in silico reverse dosimetry evaluation. Food and Chemical Toxicology, 2020, 140, 111313.	1.8	21
6	Incorporation of absorption and metabolism into liver toxicity prediction for phytochemicals: A tiered in silico QSAR approach. Food and Chemical Toxicology, 2018, 118, 409-415.	1.8	21
7	A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines. Cell Biology and Toxicology, 2017, 33, 407-421.	2.4	61
8	Identification of acetylcholinesterase inhibitors using homogenous cellâ€based assays in quantitative highâ€throughput screening platforms. Biotechnology Journal, 2017, 12, 1600715.	1.8	10
9	Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. Drug Testing and Analysis, 2016, 8, 307-310.	1.6	9
10	Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells. Methods in Molecular Biology, 2016, 1473, 63-70.	0.4	1
11	CYP3A4 inhibition by Psoralea corylifolia and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells. Toxicology Reports, 2015, 2, 530-534.	1.6	21
12	Sex hormone modulation of both induction and inhibition of CYP1A by genistein in HepG2/C3A cells. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 426-431.	0.7	6
13	A fluorescence assay for measuring acetylcholinesterase activity in rat blood and a human neuroblastoma cell line (SH-SY5Y). Journal of Pharmacological and Toxicological Methods, 2015, 76, 15-22.	0.3	28
14	Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells. Cell Biology and Toxicology, 2015, 31, 221-230.	2.4	19
15	Electron spin resonance spectroscopy for the study of nanomaterial-mediated generation of reactive oxygen species. Journal of Food and Drug Analysis, 2014, 22, 49-63.	0.9	163
16	Inhibition of monoamine oxidase (MAO) by Î²-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells. Toxicology in Vitro, 2014, 28, 403-410.	1.1	29
17	Use of the Combination Index to determine interactions between plant-derived phenolic acids on hepatotoxicity endpoints in human and rat hepatoma cells. Phytomedicine, 2013, 20, 461-468.	2.3	15
18	Effects of dietary phenolics and botanical extracts on hepatotoxicity-related endpoints in human and rat hepatoma cells and statistical models for prediction of hepatotoxicity. Food and Chemical Toxicology, 2011, 49, 1820-1827.	1.8	19

#	Article	IF	Citations
19	Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats. Drug Metabolism and Disposition, 2010, 38, 1779-1784.	1.7	248
20	Regioselective Glucuronidation of Tanshinone IIa after Quinone Reduction: Identification of Human UDP-Glucuronosyltransferases, Species Differences, and Interaction Potential. Drug Metabolism and Disposition, 2010, 38, 1132-1140.	1.7	28
21	Effects of Short-Term and Long-Term Pretreatment of Schisandra Lignans on Regulating Hepatic and Intestinal CYP3A in Rats. Drug Metabolism and Disposition, 2009, 37, 2399-2407.	1.7	47
22	Characterization of Pharmacokinetic Profiles and Metabolic Pathways of 20(S)-Ginsenoside Rh1in vivoandin vitro. Planta Medica, 2009, 75, 797-802.	0.7	41
23	Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats. Journal of Pharmaceutical Sciences, 2009, 98, 4391-4401.	1.6	86
24	An approach to identifying sequential metabolites of a typical phenylethanoid glycoside, echinacoside, based on liquid chromatographyâ€“ion trap-time of flight mass spectrometry analysis. Talanta, 2009, 80, 572-580.	2.9	65
25	Determination of 20(S)-Ginsenoside Rh1 and its Aglycone 20(S)-Protopanaxatriol in Rat Plasma by Sensitive LC-APCI-MS Method and its Application to Pharmacokinetic Study. European Journal of Mass Spectrometry, 2009, 15, 57-65.	0.5	6
26	Drugs as CYP3A Probes, Inducers, and Inhibitors. Drug Metabolism Reviews, 2007, 39, 699-721.	1.5	171
27	Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacologica Sinica, 2006, 27, 1253-1258.	2.8	32